The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:1c41e532bc679ddee32d2459c123b550]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:1c41e532bc679ddee32d2459c123b550]
Bio2RDF identifier
1c41e532bc679ddee32d2459c123b550
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1c41e532bc679ddee32d2459c123b550
measure [clinicaltrials_vocabulary:measure]
The primary efficacy endpoint ...... weeks of randomised treatment.
time frame [clinicaltrials_vocabulary:time-frame]
identifier
clinicaltrials_resource:1c41e532bc679ddee32d2459c123b550
title
The primary efficacy endpoint ...... randomised treatment. week 12
@en
type
label
The primary efficacy endpoint ...... 1e532bc679ddee32d2459c123b550]
@en